Spacova Irina, Binda Sylvie, Ter Haar Jessica Anne, Henoud Solange, Legrain-Raspaud Sophie, Dekker James, Espadaler-Mazo Jordi, Langella Philippe, Martín Rebeca, Pane Marco, Ouwehand Arthur C
Research Group Environmental Ecology and Applied Microbiology, Department of Bioscience Engineering, University of Antwerp, Antwerp, Belgium.
Rosell Institute for Microbiome and Probiotics, Montreal, QC, Canada.
Front Microbiol. 2023 Dec 19;14:1272754. doi: 10.3389/fmicb.2023.1272754. eCollection 2023.
Application of beneficial microorganisms as probiotics targets a broad range of intended uses, from maintaining health and supporting normal bodily functions to curing and preventing diseases. Currently, three main regulatory fields of probiotic products can be defined depending on their intended use: the more similar probiotic foods and probiotic dietary supplements, and live biotherapeutic products. However, it is not always straightforward to classify a probiotic product into one of these categories. The regulatory nuances of developing, manufacturing, investigating and applying each category of probiotic products are not universal, and not always apparent to those unfamiliar with the various global probiotic regulatory guidelines. Various global markets can be significantly different regarding legislation, possible claims, market value and quality requirements for the development and commercialization of probiotic products. Furthermore, different probiotic product categories are also linked with variable costs at different stages of product development. This review outlines the current landscape comparing probiotic foods, probiotic dietary supplements, and live biotherapeutics as probiotic products from a regulatory lens, focusing on product development, manufacturing and production, and clinical research agenda. The aim is to inform and promote a better understanding among stakeholders by outlining the expectations and performance for each probiotic product category, depending on their intended use and targeted geographical region.
将有益微生物用作益生菌的应用目标广泛,从维持健康和支持正常身体功能到治疗和预防疾病。目前,根据益生菌产品的预期用途可定义三个主要监管领域:较为类似的益生菌食品和益生菌膳食补充剂,以及活体生物治疗产品。然而,将益生菌产品归类到这些类别之一并非总是直截了当的。开发、生产、研究和应用各类益生菌产品的监管细微差别并不统一,对于不熟悉各种全球益生菌监管指南的人来说也并非总是显而易见。在益生菌产品开发和商业化的立法、可能的宣称、市场价值和质量要求方面,各个全球市场可能存在显著差异。此外,不同的益生菌产品类别在产品开发的不同阶段也与不同的成本相关联。本综述从监管角度概述了将益生菌食品、益生菌膳食补充剂和活体生物治疗产品作为益生菌产品进行比较的当前情况,重点关注产品开发、生产制造以及临床研究议程。目的是通过概述各类益生菌产品根据其预期用途和目标地理区域的期望和表现,为利益相关者提供信息并促进更好的理解。